VALIDATION OF MR TECH OF THERAPEUTIC EFFICACY FOR DRUG DISCOV IN ALZH DISEASE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 阿尔茨海默病(AD)有望在未来几年成为所有工业化国家面临的主要公共卫生问题之一。目前还没有疾病修正疗法被证明在人类身上是有效和安全的。然而，在发现潜在的人类疾病修改疗法方面，一个限制速度的步骤是缺乏在疾病的动物模型中测试药物的有效的非侵入性方法。这一伙伴关系项目的重点是弥合这一差距。 在这个项目中，体内MRMI作为斑块负荷的衡量标准和体内MRS作为代谢物变化的衡量标准被用来衡量预防和减少阿尔茨海默病淀粉样斑块的药物发现研究中的疗效。通过使用AD的被动免疫来测试衡量疗效的能力

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alzheimer's disease (AD) is poised to become one of the major public health problems facing all industrialized nations in the coming years. No disease modifying treatment has yet been proven to be efficacious and safe in humans. A rate limiting step in discovery of potential disease modifying therapies for humans however is the absence of effective non-invasive methods of testing drugs in animal models of the disease. The focus of this Partnership project is to bridge that gap. In this project, in vivo MRMI as a measure of plaque burden and in vivo MRS as a measure of metabolite changes are employed to measure therapeutic efficacy in drug discovery studies of Alzheimer's amyloid plaque prevention and reduction. The ability to measure therapeutic efficacy is tested by using passive immunization of the AD